Oppenheimer Asset Management Inc. Has $51.83 Million Holdings in Medtronic PLC $MDT

Oppenheimer Asset Management Inc. decreased its holdings in shares of Medtronic PLC (NYSE:MDT) by 1.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 544,218 shares of the medical technology company’s stock after selling 7,855 shares during the quarter. Oppenheimer Asset Management Inc.’s holdings in Medtronic were worth $51,831,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Delos Wealth Advisors LLC acquired a new position in Medtronic in the second quarter valued at about $27,000. Corundum Trust Company INC bought a new stake in shares of Medtronic in the 3rd quarter valued at about $27,000. Valley Wealth Managers Inc. acquired a new stake in shares of Medtronic in the 3rd quarter valued at approximately $29,000. Steigerwald Gordon & Koch Inc. bought a new position in Medtronic during the 3rd quarter worth approximately $33,000. Finally, Tripletail Wealth Management LLC acquired a new position in Medtronic during the third quarter valued at approximately $34,000. 82.06% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

MDT has been the topic of several analyst reports. JPMorgan Chase & Co. increased their target price on shares of Medtronic from $90.00 to $100.00 and gave the stock a “neutral” rating in a report on Thursday, November 13th. Citigroup started coverage on Medtronic in a research note on Tuesday, February 3rd. They set a “buy” rating and a $117.00 price objective on the stock. Barclays lifted their target price on Medtronic from $111.00 to $116.00 and gave the stock an “overweight” rating in a report on Thursday, January 8th. Weiss Ratings restated a “buy (b-)” rating on shares of Medtronic in a report on Monday, December 29th. Finally, CICC Research started coverage on Medtronic in a report on Friday, January 30th. They set an “outperform” rating on the stock. Fifteen investment analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Medtronic presently has an average rating of “Moderate Buy” and a consensus target price of $110.67.

Medtronic Stock Performance

Shares of Medtronic stock opened at $102.89 on Monday. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.42 and a quick ratio of 1.80. The firm has a market cap of $131.91 billion, a price-to-earnings ratio of 27.73, a price-to-earnings-growth ratio of 2.71 and a beta of 0.71. The stock’s 50-day moving average is $99.40 and its 200-day moving average is $96.16. Medtronic PLC has a one year low of $79.55 and a one year high of $106.33.

Medtronic (NYSE:MDT) last announced its earnings results on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.31 by $0.05. Medtronic had a return on equity of 14.86% and a net margin of 13.71%.The business had revenue of $8.96 billion for the quarter, compared to analyst estimates of $8.86 billion. During the same quarter last year, the firm earned $1.26 EPS. Medtronic’s revenue for the quarter was up 6.6% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Equities analysts predict that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, January 16th. Investors of record on Friday, December 26th were given a dividend of $0.71 per share. The ex-dividend date of this dividend was Friday, December 26th. This represents a $2.84 annualized dividend and a yield of 2.8%. Medtronic’s dividend payout ratio is 76.55%.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).